This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
752
ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Treatment-emergent adverse events
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) over 52 weeks of treatment. The Safety population consists of all subjects who received at least one dose of study drug in this study.
Time frame: 52 Weeks
Clinical Global Impression-Improvement in the ADP context (CGI-I-ADP) score
Time frame: 52 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ATP Clinical Research
Costa Mesa, California, United States
Neuro-Pain Medical Center
Fresno, California, United States
New Life Medical Research Center
Hialeah, Florida, United States
Reliable Clinical Research LLC
Hialeah, Florida, United States
Homestead Associates in Research Inc.
Miami, Florida, United States
Premier Clinical Research Institute Inc
Miami, Florida, United States
Advanced Clinical Research
Miami, Florida, United States
Verus Clinical Research
Miami, Florida, United States
Quantum Clinical Trials
Miami, Florida, United States
Future Care Solution, LLC
Miami, Florida, United States
...and 61 more locations